MTMartin Tauschmann

Martin Tauschmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Martin Tauschmann has a total of 198 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Is Diabetes Technology Associated With Weight Gain in Children and Adolescents With Type 1 Diabetes?

    by Julian Ziegler, Reinhard W. Holl, Torben Biester, Martin Tauschmann, Joachim Rosenbauer, Andreas Neu, Monika Flury, Jochen Seufert, Marie Auzanneau, Beate Karges


  • Open Access

    Head-to-Head Comparison of Two Automated Insulin Delivery Systems in Children with Type 1 Diabetes during a 2-Week Summer Camp: An Exploratory Prospective Study

    by Katharina Bünzel, Sabrina Sanfilippo, Othmar Moser, Julia K. Mader, Michaela Hofmann, Birgit Rami-Merhar, Martin Tauschmann

    Introduction: Automated insulin delivery (AID) systems offer superior glycaemic control compared to non-AID in children with type 1 diabetes, yet their performance during real-life challenges, such as summer camps with physical activity, remains underexplored. This study evaluated AID efficacy based on time range (70–180 mg/dL), comparing AID systems against sensor-augmented pump therapy (SAP) during a summer camp in children with type 1 diabetes. Methods: Data were collected from a 14-day diabetes camp (July 2024) involving 26 children (mean + SD age 10 ± 1.3 years), using Medtronic MiniMed 780G (n = 13), mylife CamAPS FX (n = 7), or SAP (n = 6). Continuous glucose monitoring (CGM)-derived metrics for the two AID systems and SAP were compared by means of t tests or Mann-Whitney U tests (p ≤ 0.05). Results: Both AID systems showed a similar time in range over the camp (primary endpoint, 75.5 ± 7.5% for MiniMed 780G vs. 71.1 ± 11.16% for CamAPS FX; p = 0.30). No significant differences were found for other glycaemic metrics or insulin dosage. Overnight, MiniMed 780G had less time below 54 mg/dL (0.0% [IQR: 0.0; 0.0%]) than CamAPS FX (0.4% [IQR: 0.0; 0.7%]; p = 0.024). SAP had significantly lower time in range than both AID systems (75.0% [IQR: 70.0; 81.0%] vs. 56.0% [IQR: 55.0; 66.0%]; p = 0.006). A positive correlation was found between coefficient of variation and the total number of steps (r = 0.39; p = 0.0459). Conclusions: Despite the camp’s challenges, both AID systems were safe and effective, meeting recommended CGM-derived treatment targets. Furthermore, AID systems showed superior glycaemic control compared to SAP.


  • Top Cited Papers
    Open Access

    International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024 Diabetes Technologies: Glucose Monitoring

    by Martin Tauschman, Roque Cardona-Hernandez, Daniel J. DeSalvo, Korey Hood, Dmitry N. Laptev, Anna Lindholm Olinder, Benjamin J. Wheeler, Carmel E. Smart

    The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines represent a rich repository that serves as the only comprehensive set of clinical recommendations for children, adolescents, and young adults living with diabetes worldwide. This chapter builds on the 2022 ISPAD guidelines, and summarizes recent advances in the technology behind glucose monitoring, and its role in glucose-responsive integrated technology that is feasible with the use of automated insulin delivery (AID) systems in children and adolescents.


  • Open Access

    The Use of Automated Insulin Delivery around Physical Activity and Exercise in Type 1 Diabetes: A Position Statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD)

    by Othmar Moser, Dessi Zaharieva, Peter Adolfsson, Tadej Battelino, Richard M. Bracken, Bruce A. Buckingham, Thomas Danne, Elizabeth A. Davis, Klemen Dovc, Gregory P. Forlenza, et al.

    Regular physical activity and exercise (PA) are cornerstones of diabetes care for individuals with type 1 diabetes. In recent years, the availability of automated insulin delivery (AID) systems has improved the ability of people with type 1 diabetes to achieve the recommended glucose target ranges. PA provides additional health benefits but can cause glucose fluctuations, which challenges current AID systems. While an increasing number of clinical trials and reviews are being published on different AID systems and PA, it seems prudent at this time to collate this information and develop a position statement on the topic. This joint European Association for the Study of Diabetes (EASD)/International Society for Pediatric and Adolescent Diabetes (ISPAD) position statement reviews current evidence on AID systems and provides detailed clinical practice points for managing PA in children, adolescents and adults with type 1 diabetes using AID technology. It discusses each commercially available AID system individually and provides guidance on its use in PA. Additionally, it addresses different glucose responses to PA and provides stratified therapy options to maintain glucose levels within the target ranges for these age groups.


  • Open Access

    The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD)

    by Othmar Moser, Dessi P. Zaharieva, Peter Adolfsson, Tadej Battelino, Richard M. Bracken, Bruce A. Buckingham, Thomas Danne, Elizabeth A. Davis, Klemen Dovč, Gregory P. Forlenza, et al.

    Regular physical activity and exercise (PA) are cornerstones of diabetes care for individuals with type 1 diabetes. In recent years, the availability of automated insulin delivery (AID) systems has improved the ability of people with type 1 diabetes to achieve the recommended glucose target ranges. PA provide additional health benefits but can cause glucose fluctuations, which challenges current AID systems. While an increasing number of clinical trials and reviews are being published on different AID systems and PA, it seems prudent at this time to collate this information and develop a position statement on the topic. This joint European Association for the Study of Diabetes (EASD)/International Society for Pediatric and Adolescent Diabetes (ISPAD) position statement reviews current evidence on AID systems and provides detailed clinical practice points for managing PA in children, adolescents and adults with type 1 diabetes using AID technology. It discusses each commercially available AID system individually and provides guidance on their use in PA. Additionally, it addresses different glucose responses to PA and provides stratified therapy options to maintain glucose levels within the target ranges for these age groups. Graphical Abstract


  • Open Access

    Eighteen-Month Hybrid Closed-Loop Use in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Trial

    by Julia Ware, Janet M. Allen, Charlotte K. Boughton, Malgorzata E. Wilinska, Sara Hartnell, Ajay Thankamony, Carine de Beaufort, Fiona M. Campbell, Elke Fröhlich-Reiterer, Maria Fritsch, et al.

    OBJECTIVE: We aimed to evaluate the longer-term safety and efficacy of hybrid closed-loop (CL) therapy in very young children with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: Following a 16-week multinational, randomized crossover trial comparing hybrid CL with sensor-augmented pump (SAP) therapy in 74 very young children aged 1–7 years with T1D, participants were invited to an extension phase using CL for a further 18 months. Outcomes were compared with the primary-phase SAP period and primary-phase CL period. RESULTS: After the primary study phase, 60 participants were eligible to enroll in the extension. Of these, 49 consented (mean ± SD age 6.6 ± 1.5 years) to continue use of CL for 18 months. Percentage time in range (TIR) 3.9–10.0 mmol/L was 8.4 percentage points (95% CI 6.7–10.1; P < 0.001) higher, while HbA1c was 0.4% ([5.0 mmol/mol], 95% CI 0.3–0.6 [3.7–6.2]; P < 0.001) lower during the CL extension phase compared with primary-phase SAP period. At 18 months, mean HbA1c was 6.7 ± 0.5% and TIR was 70 ± 7%, compared with 6.7 ± 0.5% and 71 ± 6% in the primary-phase CL period. Time in hypoglycemia (<3.9 mmol/L) was similar between CL extension phase and both primary-phase SAP (P = 0.31) and CL periods (P = 0.70). There were two severe hypoglycemia events and one other serious adverse event during the extension phase. One unexpected serious adverse device effect occurred. CONCLUSIONS: Use of the Cambridge hybrid CL system led to sustained improvements in glycemic control lasting more than 18 months in very young children with T1D.


  • Open Access

    Automatische Insulindosierung (AID) bei Kindern und Jugendlichen mit Typ-1-Diabetes

    by Martin Tauschmann

    Zusammenfassung: In den letzten 2 Jahrzehnten hat sich das Management von Typ-1-Diabetes (T1D) durch technologische Fortschritte erheblich verändert. Insulinpumpen und kontinuierliche Glukosemesssysteme (CGM) haben die traditionelle Basis-Bolus-Therapie und kapillare Blutzuckermessung ersetzt und sich als effektive Therapien etabliert, insbesondere im pädiatrischen Bereich.Automatisierte Insulinabgabesysteme (AID) kombinieren kontinuierliche Glukosemessung (CGM) mit Insulinpumpen im Sinne einer automatischen glukoseresponsiven Anpassung der Insulindosis. Die Nutzung von AID-Systemen nimmt rasch zu und wird von internationalen Gesellschaften in der Therapie von Kindern und Jugendlichen mit T1D empfohlen, idealerweise auch möglichst rasch nach der Diagnosestellung. In vielen Ländern entwickelten sich AID-Systeme auf diese Weise bereits zum Goldstandard in der Behandlung dieser Altersgruppen.Seit der Einführung des ersten kommerziellen AID-Systems wurden weitere Systeme entwickelt und zugelassen. Die AID-Technologie erwies sich als effektiv in der Verbesserung der glykämischen Kontrolle und zeigte auch vielversprechende Ergebnisse bei Kleinkindern, obwohl die Verfügbarkeit der Systeme in dieser Altersgruppe noch begrenzt ist.


  • Open Access

    Basal and Bolus Insulin Distribution According to Treatment Modality: Data from SWEET Diabetes Registry

    by Ferda Evin, Sascha R. Tittel, Barbara Piccini, Roque Cardona-Hernandez, Dick Mul, Nicole Sheanon, Thekla von Dem Berge, Vit Neuman, Martin Tauschmann, Damla Gökşen

    Background and Aims. The optimal basal and bolus insulin distribution in type 1 diabetes (T1D) is still controversial. Herein, we aimed to determine the variability of basal to total daily insulin dose according to treatment modality and diabetes technologies from the Better Control in Pediatric and Adolescent Diabetes: Working to Create Centers of Reference (SWEET) registry. Methods. The study cohort was generated by using the SWEET database. Patients with T1D for at least 2 years, aged between 2.5 and 18 years, with at least one clinic visit between June 2010 and June 2021, were included in the study. Four groups were composed according to treatment modality as follows: multiple daily injections (MDI) without continuous glucose monitoring (CGM); MDI with CGM; subcutaneous insulin infusion (CSII) without CGM; and CSII with CGM. Data of the participants were analyzed and compared for each treatment modality separately. Results. A total of 38,956 children and adolescents were included in the study. Of the study sample, 48.6% were female, the median (range) age was 15.2 (11.9–17.2) years, and the median diabetes duration was 6.0 (3.8–9.0) years. The distribution of treatment modality was as follows: MDI without CGM, 32.9%; MDI with CGM, 18.0%; CSII without CGM, 11.7%; and CSII with CGM, 37.3%. In unadjusted data, regardless of treatment modality, all the analyses revealed a significant association between basal dose to total daily insulin dose (BD/TDD) with male gender, younger age group, and lower HbA1c, which were all related to a decreased ratio of BD/TDD (all ). There was no association between BD/TDD and different diabetes technologies after the age, gender, and diabetes duration were adjusted. Conclusions. Herein, we showed that there was an association between lower proportions of basal to total insulin and lower hemoglobin A1c in a large cross-sectional cohort of children who had T1D. There was also an association between lower BD/TDD and younger age. There was no significant difference between BD/TDD ratios under different diabetes technologies (CGM and/or CSII).


  • Open Access

    New therapies towards a better glycemic control in youths with type 1 diabetes

    by Roque Cardona-Hernandez, Klemen Dôvc, Torben Biester, Laya Ekhlaspour, Maddalena Macedoni, Martin Tauschmann, Chiara Mameli


  • Open Access

    Time Spent in Hypoglycemia According to Age and Time of Day: Observations During Closed-Loop Insulin Delivery

    by Heba Alwan, Julia Ware, Charlotte K. Boughton, Malgorzata E. Wilinska, Janet M. Allen, Rama Lakshman, Munachiso Nwokolo, Sara Hartnell, Lia Bally, Carine de Beaufort, et al.

    Objective: We aimed to assess whether percentage of time spent in hypoglycemia during closed-loop insulin delivery differs by age group and time of day. Methods: We retrospectively analyzed data from hybrid closed-loop studies involving young children (2–7 years), children and adolescents (8–18 years), adults (19–59 years), and older adults (≥60 years) with type 1 diabetes. Main outcome was time spent in hypoglycemia P < 0.001 for difference between age groups. Time spent in hypoglycemia during nighttime (midnight–05:59) was lower than during daytime (06:00–23:59) across all age groups. Conclusion: Time in hypoglycemia was highest in the pediatric age group during closed-loop insulin delivery. Hypoglycemia burden was lowest overnight across all age groups.